Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - površinski antigeni virusa influence (hemaglutinin in nevraminidaza) seva a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cepiva - aktivna imunizacija proti podtipu h5n1 virusa influenca a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

FLAREX 1 mg/ml kapljice za oko, suspenzija স্লোভানিয়া - স্লোভেনীয় - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

flarex 1 mg/ml kapljice za oko, suspenzija

novartis pharma gmbh - fluorometolonacetat - kapljice za oko, suspenzija - fluorometolonacetat 1 mg / 1 ml - fluorometolon

Icandra (previously Vildagliptin / metformin hydrochloride Novartis) ইউরোপীয় ইউনিয়ন - স্লোভেনীয় - EMA (European Medicines Agency)

icandra (previously vildagliptin / metformin hydrochloride novartis)

novartis europharm limited - vildagliptin, metformin hidroklorid - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - icandra is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 in 5. 1 za razpoložljive podatke o različnih kombinacijah).